You searched for Measurable Residual Disease Testing - Page 3 of 15

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

September 17, 2020

The methodologies for testing MRD are evolving and finding less than 1 in 10,000 cells by flow cytometry is today’s standard definition for undetectable minimal or measurable residual disease (uMRD). There is good reason to believe that the deeper levels achievable with next generation gene sequencing (NGS), capable of finding a single cancer cell in a million cells, may be even more valuable, especially with cellular therapies such as CAR-T and transplants.

Dr. Nitin Jain Explains MRD testing by FLOW Cytometry

August 11, 2020

At ASH 2019 in Orlando, FL, Dr. Nitin Jain explained MRD testing for “minimal” or “measurable” residual disease, which may soon become recognized as the most reliable indicator of whether or when patients might have attained such a low level of disease that treatment could be discontinued (“limited” or “fixed” duration). Dr. Jain’s explanation cites MRD testing by FLOW Cytometry (testing down to 1 CLL cell in a sample of 10,000 cells).

ASH 2022: Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab, Ibrutinib, and Venetoclax in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

February 23, 2023

Fixed duration combination therapy of obinutuzumab, ibrutinib, and venetoclax with treatment adjustment based on clinical response and results of measurable residual disease testing shows high efficacy and safety for the front-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients with del (17p) or TP53 mutation offering exciting hope for what has been an unmet need for this group of patients with high-risk disease.

MRD-Guided Venetoclax Plus Obinutuzumab Therapy for CLL

February 20, 2025

Data suggests that patients with CLL who are on venetoclax plus obinutuzumab and reach undetectable MRD may be able to discontinue therapy early.

TARGETED ORAL TREATMENT OPTIONS

April 9, 2024

Targeted oral treatment options for CLL and SLL are medications taken by mouth that identify and attack specific cancer cells.

IMAGING TESTS

April 9, 2024

A variety of tests are used to capture images inside the body when chronic lymphocytic leukemia (CLL) and small
lymphocytic lymphoma (SLL) are present. Imaging tests are used to look inside the body to capture pictures that will help the healthcare team visualize what, if any, internal changes might be occurring.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: Measurable Residual Disease Testing – Page 3

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

Dr. Nitin Jain Explains MRD testing by FLOW Cytometry

ASH 2022: Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab, Ibrutinib, and Venetoclax in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

MRD-Guided Venetoclax Plus Obinutuzumab Therapy for CLL

TARGETED ORAL TREATMENT OPTIONS

IMAGING TESTS

CLINICAL TRIALS

Clinicians

Staging

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT